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DOI 10.1016/j.ccr.2010.11.015SUMMARYCancer-associated IDHmutations are characterized by neomorphic enzyme activity and resultant 2-hydroxy-
glutarate (2HG) production. Mutational and epigenetic profiling of a large acute myeloid leukemia (AML)
patient cohort revealed that IDH1/2-mutant AMLs display global DNA hypermethylation and a specific hyper-
methylation signature. Furthermore, expression of 2HG-producing IDH alleles in cells induced global DNA
hypermethylation. In the AML cohort, IDH1/2 mutations were mutually exclusive with mutations in the a-ke-
toglutarate-dependent enzyme TET2, and TET2 loss-of-function mutations were associated with similar
epigenetic defects as IDH1/2 mutants. Consistent with these genetic and epigenetic data, expression of
IDH mutants impaired TET2 catalytic function in cells. Finally, either expression of mutant IDH1/2 or Tet2
depletion impaired hematopoietic differentiation and increased stem/progenitor cell marker expression,
suggesting a shared proleukemogenic effect.INTRODUCTION
Acute myeloid leukemia (AML) pathogenesis is characterized by
recurrent chromosomal translocations and somatic mutations
that can define biologically distinct disease subtypes. AmongSignificance
Aberrant epigenetic programming is a hallmark of cancer and
which this occurs. Here we demonstrate that leukemic neom
IDH2 that generate the aberrant metabolite 2HG induce DNA h
cells. These effects are caused in part through inhibition of TE
IDH1/2- and TET2-mutant primary AML cells displayed a simila
permethylation and agene-specificmethylation signature. This
logically distinct disease subtype, and links cancer metabolism
Canthese abnormalities are mutations or rearrangement of genes
encoding aberrant transcription factors or cofactors that directly
perturb gene expression and disrupt cell differentiation and
survival. Others include gain-of-function mutations of kinases
involved in transduction of growth and proliferation signals.yet very little is known concerning the mechanisms through
orphic mutations of the citrate metabolism genes IDH1 and
ypermethylation and impair differentiation in hematopoietic
T2, a DNA demethylase enzyme also mutated in leukemia.
r defect in epigenetic programming consisting of global hy-
work identifies IDH1/2- and TET2-mutant leukemias as abio-
with epigenetic control of gene expression.
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IDH1/2 Mutations Perturb DNA Methylation in AMLHowever, in many AML cases, the identity and function of path-
ogenetic mutations remain obscure. Recent genomic
sequencing efforts in AML and in other malignancies have iden-
tified new classes of oncogenic disease alleles. One recently
identified class of genes mutated in cancer are those coding
for enzymes involved in citrate metabolism (Mardis et al., 2009;
Parsons et al., 2008). The most prevalent such mutations identi-
fied to date affect the genes for cytosolic isocitrate dehydroge-
nase 1 (IDH1) and its mitochondrial homolog IDH2. IDH1 and
IDH2 lesions occur in 70% of patients with lower-grade (grade
II-III) brain tumors such as astrocytomas, as well as in secondary
glioblastomas derived from lower-grade glial tumors (Hartmann
et al., 2009; Parsons et al., 2008; van den Bent et al., 2010; Yan
et al., 2009). IDH1 and IDH2 mutations were subsequently
observed in myeloid malignancies including de novo and
secondary AML (15%–30%) and preleukemic clonal malignan-
cies including myelodysplasia andmyeloproliferative neoplasms
(5% of chronic phase and 20% of transformed cases) (Mar-
cucci et al., 2010; Mardis et al., 2009; Paschka et al., 2010; Tef-
feri et al., 2010;Wagner et al., 2010;Ward et al., 2010). Themuta-
tional data in malignant gliomas and in myeloid malignancies
suggest that IDH1/2 mutations can occur early in disease path-
ogenesis and may drive tumorigenesis.
The precise genetic context in which IDH1/2 mutations occur
is not known, nor is the mechanism through which they
contribute to the malignant phenotype. IDH1/2 mutations are
heterozygous, with tumors retaining one wild-type copy of the
relevant IDH1 or IDH2 allele, suggesting that the mutations are
selected for an enzymatic gain of function rather than a loss of
function (Dang et al., 2009; Ward et al., 2010), and that retention
of the wild-type allele may be required for normal cellular metab-
olism. IDH1 and IDH2 are NADP+-dependent enzymes that nor-
mally catalyze the interconversion of isocitrate and alpha-keto-
glutarate (aKG; also known as 2-oxoglutarate). The most
common IDH1/2 mutations in AML and brain tumors, affecting
R132 of IDH1 or R140 and R172 of IDH2, have the common
feature of acquiring a neomorphic enzymatic activity catalyzing
the NADPH-dependent reduction of aKG to R()-2-hydroxyglu-
tarate (2HG) (Dang et al., 2009; Ward et al., 2010). Presumably, it
is the production of 2HG that provides a biological advantage
that contributes to malignant transformation. Because 2HG is
a structural analog of aKG, differing only in the substitution of
the a-keto group on aKG for a hydroxyl group, it is plausible
that generation of 2HG by mutant IDH1 and IDH2 might impair
the function of enzymes that require aKG as a substrate.
Recent epigenetic studies of large AML patient cohorts have
demonstrated that aberrant DNA methylation is a hallmark of
AML (Figueroa et al., 2010). Importantly, promoter methylation
data can be used to classify AML in distinct clusters defined by
specific patterns ofmethylation. Although a subset of DNAmeth-
ylation signatures have been found to be associated with known
genetic mutations, specific AML subsets were recognized solely
based on their DNAmethylation profiles (Figueroa et al., 2010). It
is not currently known whether there are somatic genetic events
that define any of the five epigenetically defined clusters in AML.
The recent finding that glioblastomas with a methylator pheno-
type are associated with cytosolic IDH1 mutations suggested
a potential causative link between these features, althoughmuta-
tions of the mitochondrial IDH2 enzyme were not detected in this554 Cancer Cell 18, 553–567, December 14, 2010 ª2010 Elsevier Incstudy and, as such, the relationship between IDH2mutations and
epigenetic state could not be assessed (Noushmehr et al., 2010).
In order to explore the mechanism of action of both IDH1 and
IDH2 mutations in malignant transformation, we performed
a large-scale genetic, epigenetic, and transcriptional profiling
study in a cohort of 385 de novo AML patients of%60 years of
age enrolled in a phase III multicenter Eastern Cooperative
Oncology Group (ECOG) clinical trial (Fernandez et al., 2009).
This is a different patient population from that reported previously
(Figueroa et al., 2010), although the methylation data from 344
patients in that cohort were used to validate the current results.
In this study, we tested the hypothesis that increased cellular
2HG levels induced by mutant IDH isoforms might contribute to
malignant transformation by interfering with the normal cycle of
DNA methylation and demethylation through inhibiting aKG-
dependent enzymes such as TET2.RESULTS
Mutations in IDH1 and IDH2 Are Frequent and Mutually
Exclusive in De Novo AML
Specimens (385) from a total cohort of 398 patients with de novo
AML younger than 60 years of age enrolled in the ECOG E1900
clinical trial (Fernandez et al., 2009) were subjected to DNA
sequence analysis for AML-associated recurrent mutations,
gene expression microarray profiling, and DNA methylation mi-
croarray profiling. Patient characteristics are summarized in
Table 1. High-throughput resequencing of IDH1 and IDH2 re-
vealed IDH1 R132 mutations in 6.2% of patients and IDH2muta-
tions in 8.6% of patients (6.3% R140Q and 2.3% R172K).
Patients with mutations in IDH1 or IDH2 did not differ from
IDH1/2-wild-type patients in terms of age, sex, or percentage
of bone marrow blasts at diagnosis (Table 1). No additional
somatic IDH1/2mutations were found. All IDH1 and IDH2muta-
tions were heterozygous, consistent with retention of the wild-
type allele as previously reported (Dang et al., 2009; Ward
et al., 2010). Although mutations in IDH1 and IDH2 are thought
to be mutually exclusive based on mutational studies in malig-
nant gliomas (Hartmann et al., 2009; Yan et al., 2009), occasional
rare AML patients have been reported with concurrent mutations
in both IDH1 and IDH2 (Paschka et al., 2010). In this large cohort
of patients with de novo AML, mutations in IDH1 and IDH2 were
mutually exclusive.
We then asked whether IDH1 and IDH2mutations were asso-
ciated with distinct clinical subsets of AML. We found that muta-
tions in IDH1 and IDH2 were significantly enriched in AML
patients with intermediate-risk cytogenetics. Specifically,
27.1% of patients with intermediate-risk cytogenetics harbored
a mutation in IDH1 or IDH2 versus only 12.6% of samples from
patients who presented with cytogenetic favorable or poor-risk
AML (p = 0.009). We next determined the coincidence of IDH1
or IDH2 with other commonly mutated genes in AML, namely
FMS-like tyrosine kinase 3 (FLT3), NPM1, and CEBPA, in the
same cohort. IDH1/2 mutations were significantly enriched in
patients with cytoplasmic NPM1 mutations (p = 0.01), as was
recently reported (Abbas et al., 2010; Paschka et al., 2010). In
contrast, IDH1/2 mutations were not significantly correlated
with or exclusive of CEBPA or FLT3-ITD mutations..






















wild-type (n = 300)
45.5 (18–60) 160/140 61/133/51/55 32/8 11 11 65 (3–100)
TET2 mutant (n = 28) 55 (30–60) 17/11 2/10/4/12 35.7/3.6 21.4 10.7 69.5 (20–99)
IDH1 or IDH2 mutant
(n = 57)
46.5 (18–60) 25/32 1/35/5/15 19.3/3.5 24.6 1.8 79 (11–100)
IDH1 mutant (n = 24) 46 (18–58) 10/14 1/18/0/5 16.7/0 25 4.2 79 (30–96)
IDH2 mutant (n = 33) 46.5 (24–60) 15/18 0/18/5/10 21.2/6.1 24.2 0 78 (11–100)
All patients (n = 385) 46.5 (18–60) 202/183 64/179/60/82 31.7/7 14 9.9 68 (3–100)
ITD/TKD, internal tandem duplication/tyrosine kinase domain.
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IDH1/2 Mutations Perturb DNA Methylation in AMLIDH1/2 Mutations Associate with Specific Cytosine
Methylation Distribution Profiles
We next performed DNA methylation profiling of 14,000
promoters (50,000 CpG sites) in 398 samples in the cohort
analyzed for IDH1/2 mutations using the HELP assay (HpaII
tiny fragment enrichment by ligation-mediated PCR) (Figueroa
et al., 2009). Fifteen samples did not pass our microarray quality
control criteria and were excluded from subsequent analysis.
The accuracy of the HELP assay in detecting cytosine methyla-
tion levels was validated in these patients using MassArray
Epityping, a gold-standard quantitative single-locus assay
(correlation coefficient r =0.87 in these AML patients) (see Fig-
ure S1A available online). Fifty-one AML patient samples
analyzed by the HELP assay were positive for mutations in either
IDH1 (n = 22) or IDH2 (n = 29). Unsupervised analysis of informa-
tive probe sets (see Supplemental Experimental Procedures)
using hierarchical clustering (correlation distance and Ward’s
clustering method) revealed that AMLs harboring IDH1/2 muta-
tions clustered together into two groups based on their common
DNA methylation profile, as can be observed in the graphical
representation of correlation between samples shown in
Figure 1A.
Hypermethylation Is the Dominant Feature
of IDH1/2-Mutant AMLs
In order to more specifically characterize DNA methylation in
IDH1/2-mutant patient samples,wenext carried out a supervised
analysis comparing IDH1/2-wild-type versus IDH1/2-mutant
AMLs. Using stringent criteria (absolute log2 difference in meth-
ylation > 1.5, p < 0.05 t test with Benjamini-Hochberg correction
for multiple testing [T+BH]), we identified 45 differentially methyl-
ated regions (DMRs), all of which were universally hypermethy-
lated in IDH1/2-mutant AMLs (Figure 2A; Table S1A). Thirty of
these genes could be assessed for gene expression (i.e., they
were present on the expression arrays used in this study) and
23/30 (77%) were repressed, consistent with the expected effect
of hypermethylation. Although many of these genes were also
expressed at relatively low abundance in a subset of IDH1/2-
wild-type AMLs, they are uniquely epigenetically silenced
through DNA methylation in IDH1/2-mutant AMLs. Furthermore,
as evidenced from the asymmetry observed in the volcano dot
plot in Figure 2A, in which methylation difference between
IDH1/2-mutant and -wild-type AMLs is plotted against statisticalCansignificance, we also observed a significant increase in overall
promoter DNAmethylation levels in IDH1/2-mutant AMLs versus
other AML patients, consistent with a methylator phenotype.
IDH1/2-Mutant AMLs Feature an Aberrant DNA
Hypermethylation Signature versus Normal
Bone Marrow
Wenext characterized the specific epigenetic alterations associ-
ated with IDH1/2-mutant malignant transformation by
performing a supervised analysis of HELP profiles between
a cohort of normal CD34+ cells obtained from the bone marrows
of 11 healthy individuals (NBM) and the 51 IDH1/2-mutant AMLs.
We again observed amarked increase in DNAmethylation levels
in IDH1/2-mutant AMLs, as evidenced by the asymmetry of the
dot plot of overall methylation levels (Figure 2B). Moreover, 154
genes were consistently and robustly differentially methylated
in IDH1/2-mutant AMLs versus normal bone marrow (>2 log2
methylation difference and p < 0.05 T+BH). All of these were
aberrantly hypermethylated (Figure 2B; Table S1B), and we
observed an overall trend to an inverse correlation between
methylation of these specific genes and their gene expression,
because a large proportion of these genes were >2-fold
repressed compared to normal CD34+ cells (Figure 2C). We
next investigated whether genes aberrantly methylated in
IDH1/2-mutant AMLs could be validated in an independent
cohort of AMLs carrying thesemutations. Themethylation status
of genes included in the IDH1/2 epigenetic signature was exam-
ined in a series of 344 AMLs from Erasmus University Medical
Center which were previously analyzed by HELP assays using
the samemicroarray design (Figueroa et al., 2010). IDH1/2muta-
tions were identified in 68 of these cases (Abbas et al., 2010). We
observed that the aberrantly methylated signature identified in
the E1900 cohort was comparably hypermethylated in this inde-
pendent cohort of IDH1/2-mutant AMLs (Figure 2D). Moreover,
unsupervised analysis of the 344 Erasmus cases again revealed
that the IDH1/2-mutant cases clustered together into two epige-
netically defined methylation clusters we had identified previ-
ously (clusters 5 and 7) (Figueroa et al., 2010) (Figure S1B).
AMLswith IDH1 and IDH2MutationsDisplay Similar DNA
Methylation Profiles
The fact that IDH1 and IDH2 mutations are mutually exclusive
suggests that their biological effect is similar and that theircer Cell 18, 553–567, December 14, 2010 ª2010 Elsevier Inc. 555
Figure 1. IDH1- and IDH2-Mutant AML Cases Tend to Cluster Based
on Their DNA Methylation Profiles
(A) Heatmap representation of a correlationmatrix in which each patient’s DNA
methylation profile is correlated with that of the other patients in the data set.
Patients are ordered according to the unsupervised analysis (hierarchical clus-
tering) results, so that highly correlated patients are located next to each other.
Parallel bars on the right of the heatmap have been used to indicate, from left to
right: cluster membership, IDH1 mutational status (green, WT; dark red,
mutant), IDH2 mutational status (green, WT; dark red, mutant), and combined
IDH1/2 mutational status (green, WT; dark red, mutant).
(B) Heatmap representation of a correlation matrix in which each patient’s
gene expression profile is correlated with that of the other patients in the
data set. Patients are ordered according to the unsupervised analysis (hierar-
chical clustering) results, so that highly correlated patients are located next to
each other. Parallel bars on the right of the heatmap have been used to indi-
cate, from left to right: IDH1 mutational status (green, WT; dark red, mutant),
IDH2 mutational status (green, WT; dark red, mutant), and combined IDH1/2
mutational status (green, WT; dark red, mutant).
See also Figure S1 and Table S1.
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IDH1/2 Mutations Perturb DNA Methylation in AMLimpact on cytosine methylation distribution would overlap. We
first carried out principal component analysis in order to deter-
mine whether any amount of the data set’s variance could be556 Cancer Cell 18, 553–567, December 14, 2010 ª2010 Elsevier Incexplained by which IDH gene was affected or by the type of
mutation. Principal component analysis showed that neither
the specific IDH gene affected nor the specific allele (IDH1
R132, IDH2 R172, IDH2 R140) constituted a significant source
of variance (Figures S2A and S2B). We then performed super-
vised analyses separately comparing DNA methylation in
IDH1- or IDH2-mutant AML samples to NBM samples. Consis-
tent with IDH1 and IDH2mutations having a common enzymatic
gain of function, we observed that methylation changes were
quite similar for both groups, although a greater number of genes
reached statistical significance (log2 ratio > 2 and p < 0.05 T+BH)
in IDH1-mutant compared to IDH2-mutant AML samples (268
DMRs for IDH1-mut versus 168 DMRs for IDH2-mut) (Tables
S1C and S1D). Nonetheless, 140 DMRs (83.3% of the hyperme-
thylated genes in IDH2 AML, Fisher p value < 0.0001) were
common to both signatures (Figure S2C), and the extent of over-
all promoter hypermethylation was similar (data not shown).
Furthermore, when the IDH1 and IDH2 signatures are compared
using a less stringent threshold (p < 0.05 T+BH), only four genes
in each group failed to reach statistical significance in the other
group. The data demonstrate that IDH1 and IDH2 neomorphic
mutations have similar effects on DNA methylation in AML cells.
Integrative Analysis Reveals Gene Networks Perturbed
in IDH1/2-Mutant AMLs
Next, an unsupervised analysis of gene expression profiling data
was performed. Unlike DNA methylation profiling, gene expres-
sion profiling did not define a specific transcriptional cluster(s)
based on IDH1/2 mutational status in this AML patient cohort
(Figure 1B). These data indicate that the biochemical effects of
IDH1/2 mutations affect the epigenome more extensively and
specifically than the transcriptome. Similar results were
observed in the analysis of gene expression in the Erasmus
University Medical Center cohort (not shown). However, a super-
vised analysis comparing IDH1/2-mutant AML patients to normal
CD34+ cells revealed a robust gene expression signature asso-
ciated with IDH1/2 mutations (fold difference > 2 and p < 0.001
T+BH) (Figure S2D and Table S1E). The fact that unsupervised
analysis based on gene expression does not segregate IDH1/
2-mutant AML cases suggests that subsets of the genes deregu-
lated in IDH1/2-mutant AMLsmay be shared with other leukemia
subtypes, or that gene expression in AML is affected by addi-
tional disease alleles which do not impact DNA methylation
signatures. We then performed supervised analyses comparing
the gene expression profiles of IDH1 and IDH2-mutant AMLs
to normal CD34+ cells (>2-fold change, p < 0.001 T+BH). There
was a significant degree of overlap (Fisher p value < 0.0001)
between the gene expression signatures defined by IDH1 and
IDH2 mutants, respectively (Figures S3A and S3B and Tables
S1F and S1G). At a statistical cutoff of p < 0.05 (T+BH), only
1.3% and 2.5% of IDH1 and IDH2 signature genes did not
overlap, respectively, further underlining the functional similarity
of these alleles. We next combined the genes contained within
the aberrant IDH1/2-mutant gene expression and DNA methyla-
tion signatures, and integrated them in order to identify biological
pathways and functions that are perturbed in these specific
leukemias. This integrative pathway analysis of aberrantly meth-
ylated and expressed genes revealed a significant overrepresen-
tation of genes involved in pathways known to contribute to.
Figure 2. IDH1/2-Mutant AMLs Have a Markedly Aberrant Hypermethylated DNA Profile
(A) Left: heatmap representation of a two-dimensional hierarchical clustering of genes identified as differentially methylated between IDH1/2-mutant primary AML
cases (indicated by the red bar) and IDH1/2-wild-type cases (indicated by the purple bar). Each row represents a probe set and each column represents a patient.
Right: dot plot of methylation difference between IDH-mutant and IDH-wild-type AMLs (biological significance) versus statistical significance (log10 [BH
p value]). Red points indicate probe sets identified as differentially methylated between the two types of AML.
(B) Left: heatmap representation of a two-dimensional hierarchical clustering of genes identified as differentially methylated between IDH1/2-mutant primary AML
cases (Mut; red bar) and normal CD34+ bonemarrow cells (NBM; blue bar). Each row represents a probe set and each column represents a patient. Right: dot plot
of methylation difference between IDH1/2-mutant AMLs and normal CD34+ bonemarrow cells (biological significance) versus statistical significance (log10 [BH
p value]). Red points indicate probe sets identified as differentially methylated between the two groups.
(C) Boxplot illustrating the averagemethylation difference between IDH1/2-mutant AMLs versus normal CD34+ cells (left) and average gene expression difference
between IDH1/2-mutant AMLs versus normal CD34+ cells (right) of genes aberrantly methylated in IDH1/2-mutant AMLs.
(D) Heatmap illustrating the validation of the IDH1/2-mutant methylation signature in an independent cohort of 344 AMLs (IDH1/2-mutant AML, Mut; red bar;
normal CD34+ bone marrow cells, NBM; blue bar).
See also Figures S2 and S3 and Tables S2A and S2B.
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IDH1/2 Mutations Perturb DNA Methylation in AMLhematopoietic malignant transformation (Figures S3C and S3D
and Table S2A).
Expression of 2HG-Producing IDH Enzymes in Cells
Induces a Global Increase in 5-Methylcytosine
Based on the observed association of IDH1/2 mutations with
hypermethylation in AML patient samples, we next sought to
determine whether expression of mutant IDH1 or IDH2 was
sufficient to increase global levels of 5-methylcytosine in cells.
As shown previously (Ward et al., 2010), expression of R132H
mutant IDH1 or R172K mutant IDH2 in 293T cells led to a
marked elevation of 2HG levels compared with expression of
the corresponding wild-type enzymes (Figures 3A and 3B).
We next determined the level of 5-methylcytosine in these cells
by immunofluorescence staining with 5-methylcytosine-spe-
cific antibody (Figure S4A) and quantified the fluorescence
intensity in >200 cells. Mutant IDH1 or IDH2 expression
resulted in a statistically significant increase in 5-methylcyto-
sine compared to cells expressing wild-type IDH1 or IDH2 (Fig-
ure 3C). Overexpression of wild-type IDH2 also led to a small
but significant increase in 5-methylcytosine levels compared
to vector control, consistent with the small 2HG elevation
observed in these cells. The increase in 5-methylcytosine
correlated well with the levels of 2HG measured in the cells.
To extend these findings to hematopoietic cells, wild-type or
R172K mutant IDH2 were stably expressed in mouse myeloid
progenitor 32D cells, which normally express wild-type forms
of IDH1, IDH2, and TET2. Expression of wild-type and
mutant IDH2 protein was confirmed by western blot. 2HG levels
were measured by gas chromatography-mass spectrometry
(GC-MS) and were only induced in cells stably expressing
mutant IDH2 (Figures 3D and 3E). The levels of 5-methylcyto-
sine were assessed by slot blot of DNA extracted from the cells
using 5-methylcytosine-specific antibody. Quantification of
band intensity showed that expression of R172K mutant IDH2
led to a significant increase in global 5-methylcytosine levels
(Figure 3F). These results were also confirmed using liquid
chromatography-electrospray ionization tandem mass spec-
trometry (LC-ESI-MS/MS) and showed a similar increase in
the 5-methylcytosine level in cells expressing R172K mutant
IDH2 (Figure S4B). We also assessed 5-methylcytosine levels
using LC-ESI-MS/MS in murine primary bone marrow cells
expressing wild-type and mutant IDH1 or IDH2, and observed
an increase in 5-methylcytosine levels in cells expressing
IDH1 R132H or IDH2 R172K, but not wild-type IDH1 or IDH2
(Figure S4C). The increase in DNA methylation we observed
in hematopoietic cells after mutant IDH1/2 expression suggests
that the IDH1/2 mutants may specifically alter DNA methylation
in AML cells.
Mutations in IDH1/2 Are Mutually Exclusive
with Mutations in TET2
One potential test of whether IDH1/2 mutants contribute to
leukemogenesis through the impairment of DNA demethylation
is through assessment of IDH1/2 mutational status in tumors
with or without somatic mutations in an enzyme involved in the
removal of DNA methylation. TET2 is an Fe(II)- and aKG-depen-
dent enzyme known to display loss-of-functionmutations in AML
and other myeloid malignancies (Abdel-Wahab et al., 2009;558 Cancer Cell 18, 553–567, December 14, 2010 ª2010 Elsevier IncDelhommeau et al., 2009; Langemeijer et al., 2009). Recently,
all TET family members including TET2 were shown to catalyze
the conversion of 5-methylcytosine to 5-hydroxymethylcytosine
(5-OH-MeC) (Ito et al., 2010; Tahiliani et al., 2009). The reaction
depends on aKG, iron, and oxygen. Although the physiological
significance of 5-OH-MeC remains to be determined, it is likely
to be the intermediate in the pathway that actively demethylates
5-methylcytosine (Wu and Zhang, 2010). Importantly, expres-
sion of TET1 or TET2 in cellular systems results in a reduction
in 5-methylcytosine levels (Ito et al., 2010). Unlike other DNA
demethylases identified so far, the hydroxylation reaction does
not involve any DNA damage, suggesting an important physio-
logical function of TET2 in removing methylation marks (Ito
et al., 2010; Tahiliani et al., 2009).
We first examined the genetic status of TET2 in AML samples
wild-type or mutant for IDH1/2. As controls in analyzing for asso-
ciation with TET2 mutations, we also examined the mutational
status of 11 other genes known to be recurrently mutated in
AML (including PHF6, WT1, TP53, ASXL1, PTEN, RUNX1, KIT,
NPM1, FLT3, CEBPA, and RAS) in this same cohort. There
were 40 somatic TET2 mutations identified in 28/385 patients
(7.3% of the ECOG patient cohort). Although only 1 homozygous
TET2mutation was observed, 11 of the 28 TET2-mutant patients
had >1 TET2 mutation, consistent with previous studies report-
ing biallelic TET2 mutations. Of the 40 TET2 mutations, 40%
were insertions/deletions resulting in a frameshift mutation,
30% were nonsense mutations, and 30% were somatic
missense mutations. AML patients with TET2 mutations did not
differ from TET2-wild-type patients in terms of age, sex, cytoge-
netic risk, or percentage of bone marrow blasts at diagnosis.
TET2-mutant patients also did not differ from TET2-wild-type
AML patients in frequency of mutations in FLT3, NPM1, or
CEBPA.
In contrast to the other genes analyzed, the relationship
between IDH1/2 and TET2 mutations was striking in this AML
cohort. Although IDH1, IDH2, and TET2 mutations were each
identified in a significant proportion of patients in our study, there
was a statistically significant inverse correlation between IDH1/2
and TET2 mutations in AML (p = 0.009, left-tailed Fisher’s exact
test). Specifically, we did not identify a single patient with
concurrent mutations in TET2 and in IDH1 or IDH2; 0/57 IDH1/
2-mutant cases were TET2-mutant versus 28/300 IDH1/2-wild-
type AML cases (Figure 4). These data suggest that TET2 and
IDH1/2 mutations form a distinct mutational class in AML, and
that IDH1/2 mutations and TET2 mutations have overlapping
roles in AML pathogenesis.
IDH Mutation Inhibits the Hydroxylation
of 5-Methylcytosine by TET2
TET2 has the classical features of an aKG-Fe(II) dioxygenase,
and requires aKG in order to mediate 5-methylcytosine hydrox-
ylation (Ito et al., 2010; Tahiliani et al., 2009). The five-carbon
dicarboxylic acids 2HG and aKG are chemically analogous.
The substitution of the keto (oxo) group on aKG to a hydroxyl
group on 2HG could potentially interfere with Fe(II) binding and
stabilization of the reaction intermediate. We therefore hypothe-
sized that 2HG produced by mutant IDH might inhibit the
hydroxylation reaction of 5-methylcytosine by TET2. To test
this hypothesis, we expressed FLAG-tagged TET2 in 293T cells..
Figure 3. Expression of 2HG-Producing IDH Proteins Increases Global 5-Methylcytosine Levels
(A) 293T cells were transiently transfected with empty vector, wild-type, or R132Hmutant IDH1, or wild-type or R172Kmutant IDH2. After 3 days, cells were lysed
and assessed for IDH1 expression levels by western blot, and then reprobed for IDH2. b-actin antibody was used as a control.
(B) Cells transfected in parallel to those lysed in (A) were extracted for intracellular metabolites. Metabolites were then derivatized with MTBSTFA (N-methyl-N-
tert-butyldimethylsilyltrifluoroacetamide) and analyzed by GC-MS. Shown is the quantitation of 2HG signal intensities relative to the intrasample glutamate
signals for a representative experiment.
(C) Global DNA methylation levels in cells were analyzed 3 days following transfection by immunofluorescence using antibody against 5-methylcytosine. Quan-
tification of fluorescence intensities from one experiment is shown. Data are representative of three independent experiments.
(D) 32D cells were transduced with empty retroviral vector or with wild-type or R172K mutant IDH2, selected in 2.5 mg/ml puromycin for 7 days, and then lysed to
confirm stable expression of IDH2. Tubulin antibody was used as a control.
(E) Cells were extracted for their intracellular metabolites which were then derivatized with MTBSTFA and analyzed by GC-MS. Shown are representative gas
chromatographs from wild-type and mutant IDH2-expressing cells depicting the derivatized metabolites eluting between 31.3 and 33.5 min, including 4-oxopro-
line (4-oxo Pro), glutamate (Glu), and 2HG. Metabolite abundance refers to GC-MS signal intensity.
(F) DNA was extracted from cells with stable wild-type or mutant IDH2 expression, and global DNA methylation levels were measured by slot blot using antibody
against 5-methylcytosine. Relative intensity of signals of three independent experiments was quantified. Error bars represent ±SD for triplicate experiments.
See also Figure S4.
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IDH1/2 Mutations Perturb DNA Methylation in AMLConsistent with previous findings (Ito et al., 2010; Tahiliani et al.,
2009), cells expressing TET2 showed higher levels of 5-OH-MeC
in the nucleus as detected by immunofluorescence staining with
5-OH-MeC-specific antibody. Cotransfection of TET2 with IDH1
R132H, but not wild-type IDH1, reversed this increase in 5-OH-
MeC (Figure 5A). To obtain a more quantitative assessment,
we also performed flow cytometric analysis of 5-OH-MeC fluo-Canrescence intensity. Staining with an anti-FLAG antibody allowed
us to discriminate between TET2-positive and TET2-negative
populations; importantly, the TET2-positive population showed
an 4-fold increase in the 5-OH-MeC fluorescence intensity.
Cotransfection with R132H mutant IDH1 led to an 40%
decrease in the fluorescence intensity, whereas wild-type IDH1
had no significant impact on 5-OH-MeC fluorescence intensitycer Cell 18, 553–567, December 14, 2010 ª2010 Elsevier Inc. 559
Figure 4. IDH1/2 Mutations Are Mutually Exclusive with Mutations in TET2 in De Novo AML
(A) Circos diagram revealing relative frequency and pairwise co-occurrences of mutations in IDH1 and IDH2 in de novo AML.
(B) Circos diagram revealing relative frequency and pairwise co-occurrences of mutations in TET2 in de novo AML.
(C) Two-by-two table showing that mutations in IDH1/2 and TET2 were mutually exclusive in AML (left-tailed Fisher p value: 0.009).
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IDH1/2 Mutations Perturb DNA Methylation in AML(Figure 5B). Consistent with its proposed role in DNA demethyla-
tion, TET2 transfection also caused a decrease in 5-methylcyto-
sine, which could be reversed by coexpression of IDH1 R132H
mutant but not wild-type IDH1 (Figure S5). Together, these
data suggest that expression of mutant IDH is able to inhibit
the hydroxylation of 5-methylcytosine by TET2 and subsequent
DNA demethylation.
TET2-Mutant AMLs Display an Overlapping
Hypermethylation Signature with IDH1/2-Mutant AMLs
The fact that IDH1/2 and TET2 mutations are mutually exclusive
in AML and that IDH1/2 mutations induce hypermethylation and
inhibit TET2-mediated 5-hydroxymethylation suggested that
bothmutations may function by altering the cytosinemethylation
profiles of hematopoietic cells. To determine whether this is the
case, we performed a supervised analysis comparing DNA
methylation profiles of TET2-mutant AMLs to NBM. This allowed
us to identify a set of 129 DMRs (>2 log2 methylation difference
and p < 0.05 T+BH), all of which were hypermethylated in TET2
patients (Figure 6A; Table S3A). As in the case of the IDH1/2-
mutant signature, there was a strong tendency for transcript
abundance of these genes to be repressed (Figure 6B). Notably,
79 (61%) of these genes overlapped with the IDH1/2-mutant
epigenetic signature (Fisher test p value < 0.0001) (Table S3B).
We then compared the methylation signature of TET2-mutant
AML cases to AMLs that were wild-type for the IDH1/2 and TET2
loci. This analysis allowed us to determine that TET2-mutant
AMLs displayed a unique methylation signature consisting of
57 DMRs (p < 0.05 T+BH). IDH1/2-mutant AMLs also displayed
a 57-DMR signature when compared to IDH1/2-wild-type and
TET2-wild-type AMLs (>2 log2 methylation difference and560 Cancer Cell 18, 553–567, December 14, 2010 ª2010 Elsevier Incp < 0.05 T+BH). Note that this IDH1/2 signature is slightly
different from the one reported in Figure 2, because it excludes
TET2-mutant AMLs from the control group in order to make
a fair comparison. Remarkably, there was an eight-gene overlap
between this unique IDH1/2-mutant signature and the TET2-
mutant signature, which is greater than expected by chance
(Fisher exact test p value = 5.45e–13), again linking the DNA
methylation defect induced by IDH1/2 and TET2 mutations
(Table S3C).
Ninety-three percent of genes aberrantly expressed in TET2-
mutant AMLs (fold difference > 2 and p < 0.001 T+BH) were
also aberrantly expressed in IDH1/2-mutant AMLs (Fisher test p
value < 0.0001). Furthermore, when we reexamined the two
epigenetic clusters enriched in patients having IDH1/2mutations,
we found that six IDH1/2-negative cases had TET2mutations.
Similar to the case of IDH1/2, there was amarked overall trend
toward promoter hypermethylation in TET2-mutant AMLs
compared to TET2- and IDH1/2-wild-type AMLs and to NBM
CD34+ cells (Figures 6C and 6D). In order to confirm that this hy-
permethylation phenomenon was specific to IDH1/2 and TET2
mutants, we carried out a similar analysis of AML1-ETO AMLs
versus AMLs negative for this fusion gene. Despite the fact
that AML1-ETO-positive AMLs have a robust hypermethylation
signature when compared to normal CD34+ cells (Figueroa
et al., 2010), they did not display a global hypermethylation
profile when compared to other AMLs (Figure S2E).
We also examined whether loss of TET2 in cells resulted in
a similar increase in 5-methylcytosine levels as did expression
of mutant IDH1/2. Two independent short-hairpin RNAs
(shRNAs) were used to stably knock down TET2 in murine
primary bone marrow cells. LC-ESI-MS/MS analysis revealed.
Figure 5. Mutant IDH1 Expression Inhibits Hydroxylation of 5-Methylcytosine by TET2
(A) 293T cells were transiently transfected with FLAG-tagged TET2 in the absence or presence of wild-type or R132H mutant IDH1. Three days following trans-
fection, global levels of 5-methylcytosine hydroxylation were analyzed by immunofluorescence using antibody against 5-hydroxymethylcytosine (5-OH-MeC).
Representative images frommock-transfected, TET2-transfected, TET2 + IDH1WT cotransfected, and TET2 + IDH1 R132H cotransfected cells are shown. Scale
bars represent 100 mm.
(B) Transfected cells were analyzed by flow cytometry and gated as TET2 positive or negative by FLAG antibody. Representative gating is shown. Intensities of
5-OH-methylcytosine staining within the TET2-positive and -negative populations are shown as histogram overlays. Data in (A) and (B) are representative of three
independent experiments. FSC, forward scatter.
See also Figure S5.
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IDH1/2 Mutations Perturb DNA Methylation in AMLthat expression of validated TET2 shRNA constructs or IDH1/2
mutations in murine primary bone marrow cells led to an
20% increase in 5-methylcytosine levels (Figure S4C). These
data suggest that loss-of-function mutations in TET2 and
IDH1/2 mutations contribute to leukemogenesis through
a shared mechanism that disrupts DNA demethylation.CanGATA and EVI1 Binding Sites Are Enriched in Aberrantly
Methylated Loci of IDH1/2-Mutant AMLs
DNA motif analysis in the promoter regions of genes associated
with the identified DMRs in IDH1/2-mutant AMLs revealed
a statistically significant enrichment of the GATA and EVI1
consensus DNA binding sequences (Figure S3E), twocer Cell 18, 553–567, December 14, 2010 ª2010 Elsevier Inc. 561
Figure 6. TET2-Mutant AML Is Associated with a Hypermethylation Phenotype
(A) Heatmap representation of a two-dimensional hierarchical clustering of genes identified as differentially methylated between TET2-mutant primary AML cases
(Mut; red bar) and normal CD34+ bone marrow cells (NBM; blue bar). Each row represents a probe set and each column represents a patient.
(B) Boxplot illustrating the average methylation difference between TET2-mutant AMLs versus normal CD34+ cells (left) and average gene expression difference
between TET2-mutant AMLs versus normal CD34+ cells (right) of genes aberrantly methylated in TET2-mutant AMLs.
(C) Dot plot of methylation difference between TET2-mutant AMLs and normal CD34+ bone marrow cells (biological significance) versus statistical significance
(log10 [BH p value]). Red points indicate probe sets identified as differentially methylated between the two groups.
(D) Dot plot of methylation difference between TET2-mutant AMLs and TET2- and IDH1/2-wild-type AMLs (biological significance) versus statistical significance
(log10 [BH p value]). Red points indicate probe sets statistically significant between the two groups.
See also Tables S3A–S3C.
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IDH1/2 Mutations Perturb DNA Methylation in AMLtranscription factor classes known to recruit chromatin-modi-
fying enzymes and to directmyeloid differentiation (e.g., Lugthart
et al., 2010; Spensberger and Delwel, 2008; Stopka et al., 2005).
Notably, out of the 164 genes in the IDH1/2-mutant methylation
signature, 65 (40%) are known GATA2 direct target genes, and
31 (19%) are known to be GATA1 direct targets (Table S2B)
(Fujiwara et al., 2009). Additionally, in our patient cohort,
GATA1wasaberrantly hypermethylated and silenced specifically
in IDH1-mutant AMLs (not shown). These data suggest that aber-
rant methylation in IDH1/2-mutant AMLs may perturb the func-
tion of transcription factors which control myeloid differentiation.562 Cancer Cell 18, 553–567, December 14, 2010 ª2010 Elsevier IncExpression of IDH2 Mutants as Well as Loss of TET2
Increase Expression of Stem Cell Markers and Impair
Myeloid Differentiation
Analysis of the aberrant DNA methylation and gene expression
signatures of IDH1/2-mutant AMLs suggested a role for these
genetic lesions in impairing myeloid differentiation. To investi-
gate the biological significance of IDH1/2 mutations, the effects
of stable expression of wild-type, R172K mutant, or R140Q
mutant IDH2 were examined in 32D myeloid cells and primary
mouse bone marrow cells. Expression of mutant IDH2, but not
of wild-type IDH2, resulted in an 40% increase in C-Kit.
Figure 7. IDH2-Mutant Expression and TET2 Knockdown in Hematopoietic Cells Impairs Differentiation
(A) 32D cells retrovirally transducedwith empty vector, IDH2WT, IDH2 R140Q, IDH2 R172K, or three independent shRNAs against mouse TET2were analyzed for
C-Kit expression by flow cytometry. Intensities of fluorescence signals are depicted as histograms.
(B) Primary mouse bone marrow cells were retrovirally transduced with MIGR1 vector, IDH2WT, IDH2 R140Q, or two shRNAs against mouse TET2. GFP-positive
cells were sorted and expanded in methylcellulose media for 14 days. Cells were analyzed for Mac-1 and C-Kit expression by flow cytometry.
(C) Cells treated as in (B) were analyzed for Mac-1 and Gr-1 expression by flow cytometry.
(D) Murine primary bone marrow cells were retrovirally transduced with MIGR1 vector, IDH2 WT, IDH2 R140Q, or two shRNAs against mouse TET2. Cells were
grown in liquid culture for 5 days ex vivo and assessed for the percentage of LSK cells out of the total lineage-negative, GFP-positive cell population.
See also Figure S6.
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IDH1/2 Mutations Perturb DNA Methylation in AMLexpression in 32D cells stably expressing IDH2 constructs (p =
0.04) (Figure 7A). Likewise, shRNA-mediated stable knockdown
of Tet2 expression by 40%–80%with three different shRNAs re-Cansulted in a significant increase in C-Kit expression (p = 0.02) (Fig-
ure 7A; Figure S6A). We next assessed the effects of wild-type
and mutant IDH2 expression in murine primary bone marrowcer Cell 18, 553–567, December 14, 2010 ª2010 Elsevier Inc. 563
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IDH1/2 Mutations Perturb DNA Methylation in AMLcells, and demonstrated that expression of mutant, but not wild-
type IDH2, resulted in an increase in C-Kit expression in murine
primary bone marrow cells after 14 days of growth in methylcel-
lulose (Figure 7B) as well as after 5 days of growth in ex vivo
liquid culture under myeloid differentiation conditions (Figures
S6B and S6C). After 14 days in methylcellulose, 71.6% of
IDH2 R140Q-expressing cells were C-Kit positive compared
with 45% of IDH2-wild-type-expressing cells. Likewise, stable
shRNA-mediated knockdown of Tet2 (50%–70% Tet2 mRNA
expression levels) in murine bone marrow cells resulted in
a >50% increase in C-Kit expression after 14 days of growth
in methylcellulose such that 57.9%–62.1% of cells with Tet2
knockdown expressed C-Kit compared with 47.6% of empty-
vector-treated cells (Figure 7B; Figure S6B). We also assessed
the effects of loss of Tet2 as well as expression of IDH2
R140Q and wild-type IDH2 on the differentiation of murine
bone marrow cells. Importantly, we found that mutant IDH2
expression as well as Tet2 loss, but not wild-type IDH2 expres-
sion, results in a reduced expression of the mature myeloid
markers Gr-1 and Mac-1 (Figure 7C). After 14 days in methylcel-
lulose culture, 7.8% of empty-vector-treated cells and 9.5% of
IDH2-wild-type-expressing cells were Mac-1/Gr-1 double posi-
tive. In contrast, bone marrow cells expressing IDH2 R140Q
(2.5% of cells double positive for Mac-1/Gr-1) or with stable
Tet2 knockdown (2.9%–3.1% of cells double positive for Mac-
1/Gr-1) had a >3-fold reduction in the proportion of cells coex-
pressing these mature myeloid markers. Colony-forming units
(CFU) plating did not reveal any significant differences in types
or numbers of colonies formed among groups (Figure S6D).
We then assessed the effects of Tet2 knockdown or mutant
IDH expression on the proportion of Lin/Sca-1+/C-Kit+ (LSK)
cells, which includes hematopoietic stem cells. We found that
overexpression of IDH2 R140Q or knockdown of Tet2 in murine
primary bone marrow cells grown in liquid culture for 5 days
ex vivo demonstrated an increase in the percentage of LSK cells
compared to control cells expressing empty vector or wild-type
IDH2 (Figure 7D). Analysis of cell morphology with Wright-
Giemsa staining also revealed an increase in the proportion of
immature myeloid progenitors (Figure S6E). These data suggest
that expression of IDH2 mutants or reduction in Tet2 expression
results in similar effects on hematopoietic differentiation with
a concordant increase in the proportion of hematopoietic
stem/progenitor cells and in inhibition of normal myeloid
differentiation.
DISCUSSION
The combination of DNA methylation, DNA sequencing, and
gene expression profiling offers the possibility of defining new
subsets of AML and gaining additional insight into AML patho-
genesis. Although we have previously shown that aberrant
DNA methylation patterning is a characteristic feature of AML
(Figueroa et al., 2010), here we demonstrate that IDH1/2-mutant
AML is associated with more extensive promoter hypermethyla-
tion compared to other AML subtypes. In addition to the global
increase in promoter methylation, IDH1/2-mutant AMLs display
a robust and unique epigenetic signature, consisting almost
entirely of hypermethylated genes, indicating that aberrant
cytosine methylation in IDH1/2-mutant AML affects specific564 Cancer Cell 18, 553–567, December 14, 2010 ª2010 Elsevier Incloci with known and putative roles in leukemogenesis. Impor-
tantly, we validated these findings in a second cohort of 344
patients in which we had previously defined five AML clusters
based on distinct epigenetic signatures without known genetic
or molecular features (Figueroa et al., 2010). We now demon-
strate that two of those five epigenetically distinct clusters of
AML patients are defined by IDH1/2 mutations.
Leukemias harboring translocations or mutations in transcrip-
tional regulators such as AML1-ETO, CBFB-MYH11, PML-
RARA, MLL, and CEBPA each display their own specific and
distinct epigenetic signatures in our previously reported cohort
(Figueroa et al., 2010) and in the ECOG cohort which is the focus
of our current study (data not shown). This is not surprising,
because it is expected that mutations which disrupt hematopoi-
etic transcription factors would have an impact on epigenetic
gene regulation. In contrast, FLT3 mutations, which activate
signaling pathways without a known role in affecting the
epigenetic state, are not associated with a mutation-specific
epigenetic signature in AML (Figueroa et al., 2010). It would not
necessarily be anticipated that mutant IDH1/2 proteins, which
are metabolic enzymes normally involved in citrate metabolism,
would specify an epigenetically defined disease. In previous
studies in glioma, it was suggested that IDH-mutant brain tumors
were characterized by a methylator phenotype which favors the
acquisition of IDH1/2 mutations (Noushmehr et al., 2010).
Alternatively, IDH1/2 mutations could be early events in the
process of hematopoietic transformation and precede the
stochastic acquisition and accumulation of epigenetic changes
that eventually culminate in overt AML. However, our data
suggest a more direct mechanistic link between IDH1/2 muta-
tions and dysregulated epigenetic programming in leukemia
cells. Specifically, our data suggest that DNA hypermethylation
is a consequence of mutant IDH protein expression and that
IDH1/2-mutant-mediated epigenetic effects contribute to AML
pathogenesis. Several lines of evidence support this hypothesis.
First, there was an inverse correlation between gene expression
andmethylation among the IDH1/2methylation signature genes,
and many of these genes have known or suspected roles in
oncogenesis. Second, we show that expression of IDH1/2-
mutant proteins resulted inmarked increases in DNAmehylation.
Third, we found that IDH1/2mutationsweremutually exclusive of
TET2 mutations in AML and that expression of mutant, but not
wild-type, IDH proteins disrupted TET2 function in cells.
We observed that IDH1/2 and TET2 mutations were mutually
exclusive in a large, genetically annotated de novo AML cohort,
suggesting that these lesions may be biologically redundant.
TET2 is a member of a family of aKG-dependent enzymes that
catalyze cytosine 5-hydroxymethylation and induce subsequent
demethylation of DNA (Ito et al., 2010; Tahiliani et al., 2009). TET2
loss of function would be anticipated to result in hypermethyla-
tion, and the data reported here support this scenario. Further-
more, IDH1/2 mutations, which lead to elevated levels of 2HG,
an aKG analog, might be anticipated to inhibit the function of
TET2. In support of this possibility, we observed that TET2-
and IDH1/2-mutant AMLs presented with more pronounced hy-
permethylation profiles than other AMLs and shared an overlap-
ping epigenetic signature. Most importantly, expression of IDH1/
2 mutants induced an increase in global DNA hypermethylation,
and inhibited TET2-induced cytosine 5-hydroxymethylation..
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IDH1/2 Mutations Perturb DNA Methylation in AMLThese data suggest that TET2 and IDH1/2 mutations constitute
a distinct mutational class in AML which affects the epigenetic
state; we would predict that additional mutations will be identi-
fiedwhichwill be classified into this ‘‘epigenetic regulator’’ muta-
tional class in AML and in other malignancies.
The present data do not exclude the possibility that IDH1/2-
mutant-mediated transformation is in part mediated by TET2
independent effects. Other families of enzymes that also require
aKG for their catalytic activity, including Jumonji-C domain
histone demethylases, could be affected by accumulation of
2HG in leukemic cells. Jumonji-C domain proteins can impair
the spread of DNAmethylation, alter the function of transcription
factors, and demethylate various chromatin marks including
gene-activation marks such as H3K4me3 and H3K36me3
(Tsukada et al., 2006) and gene-repressive marks such as
H3K9me3 (Yamane et al., 2006). It will therefore be important
in subsequent studies to assess the effects ofmutant IDHprotein
expression and 2HG accumulation on the function of other aKG-
dependent enzymes expressed in hematopoietic cells and on
the chromatin state of normal and leukemic stem/progenitor
cells. Moreover, it is important to note that other somatic lesions
may influence the IDH1/2- and TET2-mutant DNA methylation
profiles, which likely explains why a number of these cases did
not distribute to the two main IDH clusters. Ongoing studies of
AML genetic and epigenetic lesions will help to explain these
observations.
Although in vivo studies will be needed to specifically delineate
the effects of IDH1/2-mutant protein expression on stem/
progenitor cell function and on hematopoietic differentiation,
the data suggest that expression of IDH1/2 proteins in hemato-
poietic cells results in impairment of myeloid differentiation and
increased expression of immature cell-surface markers. Conso-
nant with these findings, we found that many of the genes
hypermethylated in the context of IDH1/2-mutant AML con-
tained DNA binding motifs for GATA1/GATA2 and EVI1, tran-
scription factors known to play a role in leukemogenesis and in
normal myeloid differentiation. These data are supported by
recent ChIP-seq data demonstrating many of these loci are in
fact GATA1 and GATA2 direct targets (Fujiwara et al., 2009).
We also found thatGATA1 is aberrantly methylated and silenced
in IDH1-mutant AMLs, implicating GATA1 loss of function might
contribute to the ability of IDH1/2-mutant enzymes to perturb
differentiation in myeloid cells. By contrast, EVI1 is known to
bind to DNA methyltransferases 3A and 3B and may directly
methylate target genes in IDH1/2-mutant leukemias (Lugthart
et al., 2010).
Collectively, the data suggest a paradigm whereby oncogenic
alterations in core cellular metabolic pathways can lead to
leukemic transformation by dysregulating the epigenetic
machinery in hematopoietic progenitors. Additionally, the data
support the notion that IDH1/2 mutants are a powerful leukemia
driver with a well-defined phenotype distinct from other AMLs,
and we propose that IDH1/2-mutant AML be considered a sepa-
rate subtype of AML. Moreover, because mutant IDH1/2 are
associated with a neomorphic function not characteristic of the
wild-type protein, targeted therapies that inhibit the neomorphic
function of mutant IDH enzymes might reverse epigenetic
patterning, promote myeloid differentiation, and improve
outcomes in IDH1/2-mutant AML.CanEXPERIMENTAL PROCEDURES
Patient Samples
Three hundred and ninety-eight AML samples were obtained at diagnosis from
patients enrolled in the Eastern Cooperative Oncology Group’s (ECOG) E1900
clinical trial (Fernandez et al., 2009). Samples were deidentified at the time of
inclusion in this study. Institutional review board approval was obtained at
Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center.
Sixteen specimens of human CD34+ bone marrow cells were provided by
the Stem Cell and Xenograft Core Facility of the University of Pennsylvania.
These studies were performed in accordance with the Helsinki protocols.
Table 1 summarizes patients’ characteristics.Statistical Analysis
Statistical analysis of demographic factors, disease characteristics, andmuta-
tional frequencies was performed using Fisher’s exact test and c2 tests for
categorical variables and t tests and Mann-Whitney U test for continuous vari-
ables. Student’s t test was used for analysis of fluorescence intensities.DNA Methylation Microarrays
High-molecular-weight DNA was isolated from mononuclear cell fractions
consisting of >90% blasts using the Puregene kit from QIAGEN. The HELP
assay was carried out as previously described (Figueroa et al., 2009; Khulan
et al., 2006), and samples were hybridized onto a custom human promoter
array covering 25,626 HpaII-amplifiable fragments (50,000CpGs), annotated
to 14,000 genes (Roche NimbleGen, design name: 2006-10-
26_HG17_HELP_Promoter, design ID: 4802).Mouse Bone Marrow Infections and Ex Vivo Liquid Culture
and CFU Assay
Bone marrow was harvested from the femurs of wild-type Black/6 mice imme-
diately after sacrifice. Animal care was in strict compliance with institutional
guidelines established by the Memorial Sloan-Kettering Cancer Center, the
National Academy of Sciences Guide for the Care and Use of Laboratory
Animals, and the Association for Assessment and Accreditation of Laboratory
Animal Care International. After red cell lysis in RBC lysis buffer (Puregene), the
bone marrow was cultured in media containing RPMI/10% FBS and murine
IL-3, IL-6, and stem cell factor (SCF). Twenty-four hours later, bone marrow
cells were infected with retroviral vectors expressing MIGR1 empty vector or
MIGR1 vector containing IDH2-wild-type, IDH2R140Q, or at least two different
shRNAs targeting mTET2. Cells were infected twice, with 24 hr between infec-
tions, and then sorted for GFP+ cells 48 hr following the second infection using
a FACSAria (BD Biosciences). IDH1/2 overexpression and TET2 knockdown
were confirmed by qRT-PCR using SYBR green quantification in an ABI
7500 sequence detection system. Primer sequences for IDH1/2 qRT-PCR
were as follows: IDH1F 50-GGGTTGGCCTTTGTATCTGA-30; IDH1R 50-TTTAC
AGGCCCAGATGAAGC-30; IDH2F 50-CGGCACTTTCAAAATGGTCT-30; IDH2R
50-GCATACTGGAAGCAGCTGTG-30. After sorting, GFP+ bone marrow cells
were placed in liquid culture or methylcellulose for colony-forming assays.
For ex vivo liquid culture, GFP+ cells expressing empty vector or IDH1/2
constructs were plated at 2 3 105/ml and grown for 4 days in StemSpan
SFEM (StemCell Technologies) supplemented with rmIL-3 (20 ng/ml), rhIL-6
(10 ng/ml), rmSCF (10 ng/ml), rmGMCSF (10 ng/ml), rmTPO (50 ng/ml), and
rhFlt3L (100 ng/ml). For CFU assays, 1 3 104 GFP-positive cells were plated
in duplicate in methylcellulose with complete cytokine mix (MethoCult GF
M3434; StemCell Technologies). Colonies were scored at 14 days after seed-
ing and followed by flow cytometric analysis of the population of cells plated in
methylcellulose.
Additional methods are explained in Supplemental Experimental
Procedures.ACCESSION NUMBERS
All arrays have been deposited in the Gene Expression Omnibus repository
(http://www.ncbi.nlm.nih.gov/geo) under accession number GSE24505.cer Cell 18, 553–567, December 14, 2010 ª2010 Elsevier Inc. 565
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Supplemental Information includes Supplemental Experimental Procedures,
six figures, and three tables and can be found with this article online at
doi:10.1016/j.ccr.2010.11.015.
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